1	Title: Real-World Performance of the Alinity m STI Assay for the simultaneous
2	detection of Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma genitalium,
3	and Trichomonas vaginalis in Clinical Specimens at a Large Tertiary Hospital
4	System in the United States
5	
6	Karen C. Rexroth M, ASCP ^{1,*} and Joshua Kostera, Ph.D. ²
7	
8	¹ Department of Veterans Affairs Medical Center, Washington DC, USA
9	² Abbott Molecular Diagnostics, Des Plaines, IL, USA
10	
11	*Corresponding author: Joshua Kostera
12	Phone 312.576.8696
13	Email: Joshua.Kostera@abbott.com
14	
15	Word count summary: 30
16	Word count abstract: 250
17	Word count text: 2992
18	Number of references: 24
19	Number of figures: 3
20	Number of tables: 5
21	
22	Conflicts of interest: Joshua Kostera is an employee of Abbott Laboratories.
23	Sources of support: Abbott Molecular provided the Alinity m STI reagents for the
24	study.

25 Summary

- 26 Evaluation of the Alinity m STI assay in a large US hospital system identified a
- ²⁷ higher prevalence of trichomonas and mycoplasma infections than chlamydia and
- 28 gonorrhoeae infections in urogenital specimens.
- 29

30 KEY MESSAGES

- 31 What is already known on this topic
- Mycoplasma genitalium and Trichomonas vaginalis are sexually transmitted
- 33 infections, however, global prevalence data vary between geographical regions, as
- 34 these sexually transmitted infections are not included in routine screening.

35 What this study adds

- This study aimed at assessing Trichomonas and Mycoplasma prevalence and
- 37 association with a positive Chlamydia and/or Gonorrhoeae result.

38 How this study might affect research, practice, or policy

- Including Mycoplasma genitalium and Trichomonas vaginalis testing in a routine
- 40 screening STI diagnostic algorithm, with cost-effective and accurate multiplex assays
- 41 can improve diagnosis to initiation of appropriate treatment.

42 Abstract

43	Background: In the US, sexually transmitted infections (STI) are reported for
44	Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) but not Trichomonas
45	vaginalis (TV) and Mycoplasma genitalium (MG). TV and MG surveillance data in the
46	US remains inadequate. We evaluated the performance of the fully automated, multi-
47	plex PCR-based Alinity m STI assay, to simultaneously detect CT, NG, TV, and MG,
48	at a large Veterans Affairs hospital system.
49	Methods: 260 urine, urogenital, and extragenital clinical specimens were tested with
50	the Alinity m STI assay and the results were compared to those from the Abbott
51	RealTime CT/NG assay in our lab and TV and MG assays run at an external
52	reference laboratory.
53	Results: Alinity m STI assay results for urine specimens had an overall percent
54	agreement (OPA) with the RealTime comparator assay of 187/187 (100.0%) for CT
55	and 186/187 (99.5%) for NG. For 20 rectal specimens, the OPA for CT was 95% and
56	for NG was 100%; for 13 oral specimens, OPA was 100% for CT and 92.3% for NG.
57	Of the urine specimens sent for TV and MG testing, 100% agreement was observed
58	between the Alinity m STI assay and TV (n=104) and MG (n=30) comparator assay
59	results.
60	Conclusions: The Alinity m STI assay is an easy-to-use, sensitive and specific
61	assay that allows high-throughput testing for common and undertested STI
62	pathogens to facilitate surveillance efforts.
63	
64	Key words: sexually transmitted infection, multi-plex assay, cellular control, NAAT,

65 diagnostic assay

66 Introduction

67	In the United States, approximately 2.5 million STIs were diagnosed in 2021, ^{1,2}
68	despite recent reports declaring that Americans are having less sex in the pandemic
69	era. ^{3,4} A recent report from the World Health Organization (WHO) estimated that
70	there were 374 million new STIs globally in 2020, with more than 1 million people
71	infected each day with 1 of the 4 most common pathogens: Chlamydia trachomatis
72	(CT; 129 million), Neisseria gonorrhoeae (NG; 82 million), syphilis (7.1 million), and
73	Trichomonas vaginalis (TV; 156 million). ⁵ The well-characterized bacterial pathogens
74	CT and NG, as well as TV and Mycoplasma genitalium (MG) are recognized STI
75	pathogens; ⁵⁻⁷ however, TV and MG are not considered reportable by CDC. ⁸
76	Undiagnosed and untreated STIs have significant and lifelong reproductive and non-
77	reproductive health consequences, and can increase the risk of acquiring or
78	transmitting HIV.8-10 Accurate diagnosis of STIs is necessary to interrupt
79	transmission pathways and initiate timely and appropriate treatment to improve long-
80	term health outcomes and avoid multidrug resistance. ^{8,11-13}
81	
82	Diagnosis of STIs can be challenging, as the pathogens cause overlapping
83	symptoms or subclinical symptoms that may be misdiagnosed or overlooked.
84	Current guidelines recommend the use of nucleic acid amplification testing (NAAT)
85	to screen for the reportable pathogens, CT and NG, and help reduce transmission
86	and guide precision treatment. ^{14,15} NAAT-based surveillance programs for TV and
87	MG would allow additional detection of subclinical or asymptomatic infections and
88	further hone treatment algorithms. ^{8,16,17}
89	

90 To reduce the time to diagnosis and detect multiple pathogens in a single specimen,

91	the Alinity m STI assay is a qualitative multiplex PCR-based test for the
92	simultaneous detection of CT ribosomal RNA sequences, NG DNA sequences, TV
93	ribosomal RNA sequences, and MG ribosomal RNA sequences extracted from
94	endocervical swab, vaginal swab, male and female urine, oropharyngeal swab, and
95	rectal swab specimens, and gynecological specimens preserved in ThinPrep
96	PreservCyt [®] Solution. ¹⁸ The assay also amplifies and detects an endogenous human
97	DNA sequence (cellular control, CC) and an internal control (IC) in every specimen
98	to confirm specimen adequacy and process validity, respectively. The reporting
99	structure of the assay releases results for any combination of CT, NG, TV, and MG
100	along with the IC and CC results for each specimen.
101	
102	In our study, we evaluated the real-world clinical performance of the Alinity m STI
103	assay compared to other commercially available molecular assay platforms for
104	detection of CT, NG, TV, and MG, as well as its utility for surveillance of TV and MG
105	infection, at the Washington DC Veterans Affairs Medical Center (DC VAMC), a
106	large tertiary hospital in the US. DC VAMC serves veterans in the District of
107	Columbia and surrounding suburbs, Maryland, and West Virginia, which has an
108	estimated veteran population of 765,000. The DC VAMC is an acute care hospital
109	that includes 7 community-based outpatient clinics, a women's clinic, infectious
110	diseases clinic, and an emergency department; specimens included in this study
111	were acquired at each of these locations. As Washington DC has the fifth highest
112	STI rate in the US, ² the DC VAMC is a favorable site for not only evaluating the
113	performance of the Alinity m STI assay but also examining the cross-sectional
114	prevalence of detected STIs compared to the latest statistics released by the CDC.
115	

116 Methods

117	The study included 3 objectives. The first was to perform an observed sensitivity
118	assessment using standard biological reference materials from a third-party
119	manufacturer (Exact Diagnostics, Fort Worth, TX) to evaluate the sensitivity of the
120	assay. The second objective was to conduct a clinical comparative evaluation in
121	which specimens were tested with the Alinity m STI assay and other commercially
122	available STI assays to determine result agreement. The third objective was an ad
123	hoc stability study evaluating individual neat urine specimens confirmed positive with
124	a STI pathogen to determine specimen integrity for up to 7 days in cold storage,
125	either refrigerated or frozen, prior to testing with the Alinity m STI assay. All statistical
126	analyses were completed using SAS version 9.3 or higher, or Microsoft Excel
127	version 2108.

128

129 **Observed sensitivity assessment**

130 To evaluate the sensitivity of the Alinity m STI assay for each of the 4 pathogens (CT, NG, TV, MG), biological reference material (Exact Diagnostics) for each 131 132 organism was used. Materials were stored and handled according to the labeling 133 instructions provided by the manufacturer. The material contains whole intact 134 biological organism in a synthetic matrix and contains preservative that is value 135 assigned using digital droplet PCR with assigned units in copies/mL. Alinity m multi-136 Collect Specimen Collection Kit stabilization buffer was used to make up a bulk 137 diluent, which was then used to prepare multiple panels where the reference material 138 was spiked to create diluted titers for each of the 4 pathogens. A range-finding study 139 was performed for each of the pathogens to determine the observed sensitivity of the

- 140 assay. This was followed by testing 10 replicates at the 2 lowest range-finding titer
- 141 levels at which the assay could detect 95% or greater of replicates.
- 142

143 Clinical comparative evaluation

144 A total of 260 deidentified adult urogenital and extragenital remnant clinical

specimens were included in this study (Figure 1), which was determined to be

- exempt by the DC VAMC IRB. Specimens were acquired after obtaining informed
- 147 consent from consecutive inpatients and outpatients at the DC VAMC. Specimens
- were collected in accordance with institutional standard practices and procedures as
- part of routine patient care and consisted of male and female urine and rectal,
- 150 oropharyngeal, vaginal, and endocervical swabs. Additional gynecological
- 151 specimens acquired for the study were collected in ThinPrep PreservCyt[®] and stored
- according to the manufacturer instructions.
- 153

154 Clinical swab specimens included in the study were dual collected using the Abbott 155 multi-Collect Specimen Collection Kit (Abbott Kit) and the Alinity m multi-Collect 156 Specimen Collection Kit (Alinity Kit). The 2 collection kits are intended for the 157 collection and transportation of male and female urine specimens, endocervical 158 swab specimens, vaginal swab specimens, oropharyngeal swab specimens, and 159 rectal swab specimens to stabilize nucleic acid for testing with the Alinity m STI 160 assay. Urine specimens sent to the laboratory were split between the 2 collection 161 kits, and approximately 2 mL of specimen was aseptically transferred to the 162 collection kit tube according to the manufacturer's instructions. All specimens once 163 added to the respective collection devices were stored refrigerated at 2-8°C for up to 164 14 days or frozen at -20°C for up to 60 days. The Alinity kit specimens were tested

165	with the Alinity m STI assay and Abbott kit specimens were tested with the Abbott
166	RealTime CT/NG assay (Abbott Laboratories). The clinical evaluation was conducted
167	using 3 lots of amplification reagents, controls, and bulk specimen extraction
168	reagents. Alinity m STI results for CT and NG were compared to the Abbott
169	RealTime CT/NG assay results. Alinity m STI results for TV and MG were compared
170	to those from specimens sent to an external reference laboratory service (Labcorp,
171	Burlington, NC). Specimens that were sent to the external reference laboratory
172	service were also collected in the Aptima Transport tube. The external laboratory
173	service tests TV using TMA technology and MG using the Sureswab $^{\scriptscriptstyle (\!R\!)}$
174	Mycoplasma/Ureaplasma Panel. Extragenital specimen testing was previously self-
175	validated for use with the Abbott RealTime CT/NG assay.

176

177 Urine specimen stability assessment

178 To evaluate neat urine specimen stability prior to processing, patients followed the 179 clean catch urine collection procedure using a sterile collection container. Specimens that were individually identified as positive for CT, NG, TV, and MG were split into 2 180 aliquots. One aliquot was refrigerated at 4°C and the other was aliquoted into 4 181 182 transport tubes containing no preservative buffer and capped. These were stored at 183 frozen at -20°C. Individual specimen aliquot tubes were used to mitigate the freeze-184 thaw impact on stability of the specimens; the impact of freeze-thaw cycles on 185 specimen stability was not assessed in this investigation. The stability testing schedule included test points on day 1, 3, 5, and 7 to simulate a delayed specimen 186 187 testing scenario. The cycle number (CN) for each specimen was recorded for each 188 test point to determine the impact of storage temperature and time on Alinity m STI 189 assay performance.

190

191 **Results**

192 Alinity m STI is sensitive for detection of all 4 pathogens

- 193 Prior to testing clinical specimens, an observed sensitivity assessment was
- 194 performed to determine the overall sensitivity of the Alinity m STI assay. The
- 195 sensitivity assessment was conducted using 1 lot of amplification reagents, controls,
- and bulk specimen extraction reagents. An initial range finding experiment was
- 197 completed (Supplemental Table s1), followed by a final sensitivity confirmation. The
- limit of detection of the Alinity m STI assay was 5 copies/mL for CT, 50 copies/mL for
- 199 NG, 50 copies/mL for TV, and 900 copies/mL for MG. Table 1 shows the final
- 200 observed sensitivity results as well as calculated conversion estimates to units
- ²⁰¹ presented in the Alinity m STI assay package insert.¹⁸
- 202

203 Alinity m STI assays produce comparable clinical results across specimen

204 **types**

205 For clinical specimens, Alinity m STI results for CT and NG were compared to Abbott 206 RealTime CT/NG assay results; Alinity m STI results for TV and MG results were 207 compared to those received from an external reference laboratory service for NAAT 208 testing. Reflecting the current state of STI testing in the US and the real-world design 209 application of the study, not all specimens included in our evaluation were ordered 210 for TV and MG testing. Based on the patient risk profile and clinical presentation, 211 specimens were ordered and sent out for TV and MG testing at the direction of the 212 patient provider. For the subset of specimens for which comparator testing results 213 were available, Alinity m STI results were compared to external assay testing for 104 214 specimens for TV and 30 specimens for MG.

215

216	Using the Abbott RealTime CT/NG assay and external laboratory service tests for TV
217	and MG as a reference, the Alinity m STI assay produced an OPA ≥92.3% for
218	extragenital specimens and \geq 99.5% for urine specimens. The clinical OPA, NPA,
219	and PPA for the Alinity m STI assay across sample types are presented in Table 2.
220	
221	Although the sample size was smaller (n=33) for extragenital specimens than for
222	urogenital specimens (n=227), the observed prevalence for CT (18.2%) and NG $$
223	(27.3%) in extragenital specimens was much higher than the mono-infection
224	urogenital prevalence for CT (5.0%) and NG (5.0%). Co-infections were also
225	detected in the study cohort; 9.0% of rectal specimens and 1.0% of urine specimens
226	were positive for both CT and NG with the Alinity m STI assay and correlated 100%
227	with the comparator assay. One (0.20%) urine specimen was positive for CT and MG $$
228	with the Alinity m STI assay, with the CT result confirmed on the Abbott RealTime
229	CT/NG assay (this specimen was not ordered for MG testing). One (3.0%) rectal
230	specimen was positive for NG and MG with the Alinity m STI assay, with the NG
231	result confirmed on the Abbott RealTime CT/NG assay (this specimen was not
232	ordered for MG testing).
233	

In the clinical specimen evaluation data set, 3 discrepant results were observed
between the Alinity m STI assay and reference tests (Abbott RealTime CT/NG or
external laboratory services TV and MG tests). The 3 descrepant results were 1
urine and 1 oral specimen discrepant for NG and 1 rectal specimen descrepant for
CT results. All 3 specimens had very high CNs, indicating very low levels of target
pathogen. All specimens generated valid results on the Alinity m STI assay (valid IC

and CC results) with no inhibition observed, including for extragenital rectal and

oropharyngeal swab specimen types (data not shown).

242

243 The number and sources of clinical specimens included in this study are summarized

- in Table 3 along with the Alinity m STI assay testing results. Twenty-nine specimens
- in ThinPrep PreservCyt[®] were tested with the Alinity m STI assay; however, all
- specimens were negative for CT, NG, TV, and MG. Of note, the combined total
- 247 prevalence of non-reportable pathogens TV and MG (n=31) was observed to be
- 15.2% in the urogenital study population compared to the combined prevalence of
- CT and NG (n=25), which was observed to be 10.1%.
- 250

251 Urine specimens are stable for up to 7 days at 4°C or -20°C

- 252 The objective of this study component was to investigate potential influence of
- storage temperature and time on the stability of neat urine specimens, based on the
- 254 CN values from the Alinity m STI assay.
- 255

All CN data points for both refrigerated and frozen storage conditions were within 2

SD of the average CN for all specimens in the study, indicating that there were no

statistically significant data points that could suggest significant degradation of the

- specimens, data shown in supplemental Table s2.
- 260
- 261
- 262
- 263
- 264

265 Discussion

266	Our clinical findings are consistent with those of another recent study ²⁰ comparing
267	the clinical performance of the Alinity m STI assay with Abbott RealTime CT/NG
268	assay, which showed similar agreement for detecting CT, NG, and MG in patient
269	specimens. A separate multicenter study also showed high correlations between the
270	Alinity m STI assay and various comparator assays. ²¹ In our study, across all
271	specimen types in the entire study cohort, 25.0% (n=65/260) of patient specimens
272	were found to have either a mono or co-infection STI. STIs that are not accurately
273	diagnosed will continue to challenge public health causing significant and serious
274	long-term health consequences for patients.
275	
276	Historically, MG has not been routinely tested at DC VAMC; as all 4 pathogens can
277	be simultaneously detected by the Alinity m STI assay, it is notable that MG was
278	observed to have the highest positivity rate compared to the other STI pathogens in
279	our specimen cohort. 12.6% of male urine specimens were positive for MG,
280	compared to 8.4% for CT and 7.7% for NG. For female urine specimens in our study,
281	MG was detected in 6.8% of specimens, also higher than that detected for CT
282	(2.27%), and no cases of NG were detected. Although 187 urogenital specimens
283	were not ordered for MG testing, 16 (~10%) of those were positive for MG and
284	negative for CT, NG, and TV on the Alinity m STI assay. All CT and NG results were
285	confirmed with comparator testing and 109 out of the 260 specimens were ordered
286	and confirmed for TV with comparator testing. MG infections are generally
287	asymptomatic in both men and women, contributing up to 35% of non-chlamydial
288	non-gonococcal urethritis in men and linked to cervicitis and pelvic inflammatory
289	disease in women. ⁶ Clinical treatment failures and antimicrobial-resistant MG are a

290 significant concern, and rising incidence rates of unknown magnitude have 291 complicated the clinical management of this infection. The consequences of an 292 undiagnosed and untreated MG infection can be severe; our findings support the 293 need for STI multi-plex testing to include MG. 294 295 Globally, TV is the most common, curable non-viral STI that is often associated with 296 serious health consequences including preterm birth, low-birthweight infants, and 297 infertility, as well as increasing the risk for acquisition and transmission of human immunodeficiency virus (HIV).^{5,8} The epidemiology of TV in men is less delineated 298 299 than for women, for the male urine specimens included in our study, we observed a 300 4.9% positivity rate for TV. Risk factors for TV in women include older age, race, impoverished socioeconomic status, and multiple sexual partners.¹⁰ In our study, 301 302 4.5% of female urine specimens were positive for TV. At present, neither TV nor MG 303 meet all the criteria for confirmed cases to be reported to the CDC, including for 304 women who are pregnant. 305 306 Our study findings support the use of NAATs for testing and surveillance of STI 307 pathogens such as MG and TV. Simultaneous detection of the 4 major STI 308 pathogens by the Alinity m STI assay would simplify the implementation of MG/TV 309 surveillance programs in health systems that already report NG and CT infections. 310 TV and MG surveillance programs can lead to evidence-driven changes in the STI 311 diagnostic algorithm, with cost-effective and accurate multiplex assays moving 312 patients quickly from diagnosis to initiation of appropriate treatment. 313

314 Infections at extragenital sites are typically asymptomatic and latent, making clinical 315 diagnosis challenging in the absence of a sensitive and specific molecular assay. 316 Extragenital specimens were included in our study to evaluate the performance of 317 the Alinity m STI assay with oropharyngeal and rectal swabs. Extragenital testing is 318 not always part of routine STI screening algorithms, although recent studies have 319 highlighted the STI incidence rate at the oropharynx and rectum, leading to a shift in practice to include screening of extragenital sites.¹⁹ In total, 33 extragenital 320 321 specimens were submitted for testing in our study. Four out of 13 oropharyngeal 322 specimens (30.8%) were positive for NG. Three out of 20 rectal specimens (15.0%) 323 were positive for both CT and NG, 5 (25.0%) were positive for NG, 4 (20.0%) were 324 positive for CT, and 1 (5.0%) was positive for both NG and MG. The extragenital 325 specimens included in this study were primarily collected from male patients (n=32), 326 with only 1 extragenital specimen from a female patient. Overall, men who have sex 327 with men (MSM) demonstrate a higher prevalence of extragenital infection compared to women and men who have sex with women;²² however, extragenital STI testing 328 should be considered for both men and women.²² An increased risk of HIV 329 330 acquisition is a potential consequence of untreated extragenital infections, which can 331 serve as a potential reservoir for transmission specifically in patients with repeat gonococcal and chlamydial rectal infections.²³ Surveilling the frequency of STI will 332 333 inform how trends in screening programs change over time as HIV PrEP access 334 expands and STI screening programs become more widely adopted among PrEP users.²² 335

336

Staffing shortages and specimen transport logistical challenges can introduce unique
 impediments that reduce laboratory testing efficiency. Patient specimen hold times

339	can v	ary prior to processing into the appropriate collection device, tube, or media					
340	that is	s utilized with the testing methodology or system to analyze the specimen.					
341	Furth	ermore, current guidelines in the literature are contradictory for urine storage					
342	tempe	eratures and duration prior to analysis. The findings from our assessment suggest					
343	that co	prrectly collected neat urine specimens intended for STI testing that cannot be					
344	proces	ssed immediately maintain integrity when stored refrigerated or frozen for up to 7 days					
345	prior t	o processing. Differences in bio-metabolic profiles that can impact specimen integrity					
346	were r	not examined.					
347							
348							
349	Acknowledgements						
350	The authors would like to thank Yan Zhang, PhD, for assistance with the statistical						
351	analysis. Stacey Tobin, PhD, provided editorial support for manuscript preparation,						
352	with compensation from Abbott Laboratories.						
353 354	Refer	rences					
355	1.	Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually Transmitted Infections					
356		Among US Women and Men: Prevalence and Incidence Estimates, 2018.					
357		Sexually Transmitted Diseases. 2021;48(4):208-214.					
358		doi:10.1097/olq.00000000001355					
359	2.	Centers for Disease Control and Prevention. Sexually Transmitted Disease					
360		Surveillance 2021. 2023; https://www.cdc.gov/std/statistics/2021/default.htm.					

- 361 Accessed May 23, 2023.
- Gleason N, Banik S, Braverman J, Coleman E. The Impact of the COVID-19
 Pandemic on Sexual Behaviors: Findings From a National Survey in the

364 United States. *J Sex Med.* 2021;18(11):1851-1862.

- 365 doi:10.1016/j.jsxm.2021.08.008
- 4. Twenge JM, Sherman RA, Wells BE. Declines in Sexual Frequency among
- 367 American Adults, 1989-2014. Arch Sex Behav. 2017;46(8):2389-2401.
- 368 doi:10.1007/s10508-017-0953-1
- World Health Organization. Global progress report on HIV, viral hepatitis and
 sexually transmitted infections, 2021.
- 371 <u>https://www.who.int/publications/i/item/9789240027077</u>. Accessed June 15,
- 372 2023.
- 373 6. Manhart LE, Gaydos CA, Taylor SN, et al. Characteristics of Mycoplasma
- 374 genitalium Urogenital Infections in a Diverse Patient Sample from the United
- 375 States: Results from the Aptima Mycoplasma genitalium Evaluation Study

376 (AMES). J Clin Microbiol. 2020;58(7). doi:10.1128/JCM.00165-20

- 377 7. Newman L, Rowley J, Vander Hoorn S, et al. Global Estimates of the
- 378 Prevalence and Incidence of Four Curable Sexually Transmitted Infections in
- 2012 Based on Systematic Review and Global Reporting. *PLoS One.*

380 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304

- 381 8. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted
- Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-
- 383 187. doi:10.15585/mmwr.rr7004a1
- Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex
 Transm Infect. 2013;89(6):426-433. doi:10.1136/sextrans-2012-051005
- 10. Muzny CA. Why Does Trichomonas vaginalis Continue to be a "Neglected"
- 387 Sexually Transmitted Infection? *Clin Infect Dis.* 2018;67(2):218-220.
- 388 doi:10.1093/cid/ciy085

- 389 11. Getman D, Jiang A, O'Donnell M, Cohen S. Mycoplasma genitalium
- 390 Prevalence, Coinfection, and Macrolide Antibiotic Resistance Frequency in a
- 391 Multicenter Clinical Study Cohort in the United States. *J Clin Microbiol.*
- 392 2016;54(9):2278-2283. doi:10.1128/JCM.01053-16
- 393 12. Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current
- treatment options and resistance issues. *Infect Drug Resist.* 2017;10:283-292.
- 395 doi:10.2147/IDR.S105469
- 13. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections:
- 397 gonorrhoea and Mycoplasma genitalium. *Nat Rev Urol.* 2017;14(3):139-152.
- 398 doi:10.1038/nrurol.2016.268
- 399 14. Recommendations for the laboratory-based detection of Chlamydia
- 400 trachomatis and Neisseria gonorrhoeae--2014. *MMWR Recomm Rep.*
- 401 2014;63(Rr-02):1-19.
- 402 15. Nelson HD, Zakher B, Cantor A, Deagas M, Pappas M. Screening for
- 403 Gonorrhea and Chlamydia: Systematic Review to Update the U.S. Preventive

404 Services Task Force Recommendations. Rockville (MD)2014.

- 405 16. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit
- 406 of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis
- 407 among men and women attending a sexually transmitted diseases clinic. *Clin* 408 *Infect Dis.* 2014;59(6):834-841. doi:10.1093/cid/ciu446
- 409 17. Muzny CA, Burkholder GA, Fry KR, Austin EL, Schwebke JR. Trichomonas
- 410 vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic. Sex
- 411 *Transm Dis.* 2016;43(8):483-488. doi:10.1097/OLQ.000000000000479
- 412 18. Abbott Molecular. Alinity m STI AMP Kit [Package Insert]; 2018.

- 413 19. Chan PA, Robinette A, Montgomery M, et al. Extragenital Infections Caused
- 414 by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the
- Literature. *Infect Dis Obstet Gynecol.* 2016;2016:5758387.
- 416 doi:10.1155/2016/5758387
- 417 20. Herrmann B, Malm K. Comparison between Abbott m2000 RealTime and
- 418 Alinity m STI systems for detection of Chlamydia trachomatis, Neisseria
- 419 gonorrhoeae, and Mycoplasma genitalium. *Eur J Clin Microbiol Infect Dis.*

420 2021. doi:10.1007/s10096-020-04135-9

- 421 21. Obermeier M, Pacenti M, Ehret R, et al. Improved molecular laboratory
- 422 productivity by consolidation of testing on the new random-access analyzer
- 423 Alinity m. Journal of Laboratory Medicine. 2020;44(6):319-328.
- 424 doi:doi:10.1515/labmed-2020-0102
- 425 22. de Voux A, Bernstein KT, Kirkcaldy RD, Zlotorzynska M, Sanchez T. Self-
- 426 Reported Extragenital Chlamydia and Gonorrhea Testing in the Past 12
- 427 Months Among Men Who Have Sex with Men in the United States-American
- 428 Men's Internet Survey, 2017. *Sex Transm Dis.* 2019;46(9):563-570.
- 429 doi:10.1097/OLQ.000000000001032
- 430 23. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea
- and chlamydia reinfection is associated with increased risk of HIV
- 432 seroconversion. *J Acquir Immune Defic Syndr.* 2010;53(4):537-543.
- 433 doi:10.1097/QAI.0b013e3181c3ef29
- 434 24. Huppert JS, Reed JL, Munafo JK, et al. Improving notification of sexually
- 435 transmitted infections: a quality improvement project and planned experiment.
- 436 *Pediatrics.* 2012;130(2):e415-422. doi:10.1542/peds.2011-3326

438 Figure Legends

- **Figure 1.** Stratification of specimen types included in the clinical comparative study.

444 Tables

Pathogen	Target Concentration (Copies/mL)	Conversion Calculation Units	Average CN	High CN	Low CN	Reps Detected
CT	5	0.0023 EB/mL	36.54	37.86	34.56	10 / 10
NG	50	0.5 CFU/mL	37.97	39.94	36.69	10 / 10
TV	50	7.6E-5 TV/mL	30.33	31.16	27.36	10 / 10
MG	900	237 GE/mL	37.62	39.8	35.74	10 / 10

Table 1. Final Observed Sensitivity of the Alinity m STI Assay

CFU, colony forming unit; CN, cycle number; CT, Chlamydia trachomatis; EB, elementary bodies; GE, genome equivalents; MG, Mycoplasma genitalium; NG, Neisseria gonorrhea; TV, Trichomonas vaginalis.

449 **Table 2.** Clinical Sample Agreement

Rectal CT		M2000					
		POS	NEG	OPA	PPA	NPA	
Alipity	POS	6	0	95.0%	85.7%	100%	
Annity m	NEG	1	13	(76.39,99.11)	(48.69,97.43)	(77.19,100.00)	
Rectal NG		M2	000				
		POS	NEG	OPA	PPA	NPA	
Alinity m	POS	5	0	100%	100.0%	100.0%	
7 unity m	NEG	0	13	(82.41,100.00)	(56.55,100.00)	(77.19,100.00)	
Oral CT		M2	000				
		POS	NEG	OPA	PPA	NPA	
Alinity m	POS	0	0	100.0%		100.0%	
	NEG	0	13	(77.19,100.00)	(66.69,98.63)	(77.19,100.00)	
		1					
Oral NG		M2	000				
		POS	NEG	OPA	PPA	NPA	
Alinity m	POS	4	0	92.3%	80%	100.0%	
,	NEG	1	8	(66.69,98.63)	(37.55,96.38)	(67.56,100.00)	
		1					
Urine CT		M2000		-			
		POS	NEG	OPA	PPA	NPA	
Alinity m	POS	13	0	100.0%	100.0%	100.0%	
,	NEG	0 174		(97.99,100.00)	(77.19,100.00)	(97.84,100.00)	
		1		1			
Urine NG		M2000		-			
		POS	NEG	OPA	PPA	NPA	
Alinity m	POS	10	1	99.5%	100.0%	99.4% (96.87,99.90)	
	NEG	0	176	(97.03,99.91)	(72.25,100.0)		
				1			
Urine TV		Ap	tima				
		POS	NEG		РРА	NPA	
Alinity m	POS	9	0	100.0%	100.0% (70.09.100.00)	100.0% (97 88 100 00)	
NEG		U	177	(01.00,100.00)	(10.00,100.00)	(01.00,100.00)	
		2	Ours	ı ———			
Urine MG		Sure	Swab	0.54			
	POS	PU5	NEG		PPA	NPA	
Alinity m	PUS	21	0	100.0% (97.99.100.00)	100.0% (84.54.100.00)	100.0% (97 74 100 00)	
	INEG	U	001	(01.00,100.00)	(01.01,100.00)	(31.14,100.00)	

CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhea; NPA, negative percent agreement; OPA, overall percent agreement; PPA, positive percent agreement; TV, Trichomonas vaginalis.

Clinical Specimen Source	Total Tested	CT+	NG+	TV+	MG+
Male Urine	143	12	11	7	18
Female Urine	44	1	0	2	3
Rectal	20	7	6	0	1
Oropharyngeal	13	0	4	0	0
Endocervical / Vaginal	11	0	1	0	1
ThinPrep PreservCyt	29	0	0	0	0
Total	260	25	27	11	23

450 **Table 3.** Alinity m STI Assay Results by Clinical Specimen Type

CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhea; TV, Trichomonas vaginalis.

453 Figures

- 454
- Figure 1. Stratification of specimen types included in the clinical comparative study.



456

458 Supplemental

459	Table s1. Observed Sensitivi	y Range-Finding Results	for the Alinity m STI Assay
-----	------------------------------	-------------------------	-----------------------------

Pothogon	Levels Tested	Average CN	Reps	
Pathogen	(Copies / mL)	Average CN	Detected	
	300	35.54	3/3	
	150	35.5	3/3	
ст	75	35.96	3/3	
CI	20	37.45	3/3	
	10	37.7	3/3	
	5	38.59	2/3	
	500	32.51	3/3	
	250	33.98	3/3	
NG	100	35.45	3/3	
	50	37.00	3/3	
	40	37.93	2/3	
	150	32.00	3/3	
	75	31.85	3/3	
TV	50	31.42	3/3	
	25	N/D	0/3	
	10	N/D	0/3	
	1700	28.53	3/3	
	1500	29.27	3/3	
MG	1000	30.37	3/3	
	900	29.57	0/3	
	750	38.95	2/3	

CN, cycle number; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhea; TV, Trichomonas vaginalis.

С	T	N	G	Т	V	Μ	IG	
27.78		24.5		21	21.75		27.24	
-20°C	4°C	-20°C	4°C	-20°C	4°C	-20°C	4°C	
27.49	27.62	24	26.49	23.61	22.42	27.75	27.23	
27.96	27.75	24.25	27.13	25.1	23.37	28.69	27.55	
27.36	27.62	25.24	27.63	24.42	24.89	27.86	26.99	
27.62	27.29	25.57	27.43	26.73	25.82	28.86	27.5	
27.61	27.57	24.77	27.17	24.97	24.13	28.29	27.32	
0.26	0.20	0.76	0.50	1.32	1.52	0.57	0.26	
0.52	0.39	1.52	1.00	2.65	3.04	1.13	0.52	
	C 27 -20°C 27.49 27.96 27.36 27.62 27.61 0.26 0.52	CT27.78-20°C4°C27.4927.6227.9627.7527.3627.6227.6227.2927.6127.570.260.200.520.39	CT N 27.78 24 -20°C 4°C -20°C 27.49 27.62 24 27.96 27.75 24.25 27.36 27.62 25.24 27.62 27.29 25.57 27.61 27.57 24.77 0.26 0.20 0.76 0.52 0.39 1.52	$\begin{array}{c c c c c c c c } CT & NG \\ \hline 27.78 & 24.5 \\ \hline 27.79 & 27.62 & 24 & 26.49 \\ 27.96 & 27.75 & 24.25 & 27.13 \\ 27.36 & 27.62 & 25.24 & 27.63 \\ 27.62 & 27.29 & 25.57 & 27.43 \\ 27.61 & 27.57 & 24.77 & 27.17 \\ 0.26 & 0.20 & 0.76 & 0.50 \\ 0.52 & 0.39 & 1.52 & 1.00 \\ \hline \end{array}$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	

Table s2. Neat Urine Stability Summary

CFU, colony forming unit; CN, cycle number; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhea; SD, standard deviation; TV, Trichomonas vaginalis.